Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Diagnostics Biochemistry and molecular biology, Oncology

Standardizing minimal residual disease (MRD) assessment in lymphoid malignancies using NGS

sponsored by Adaptive Biotechnologies

Available On-Demand

Wednesday November 4th

Available through Adaptive Biotechnologies, the FDA-cleared clonoSEQ® Assay is a highly sensitive, specific, and standardized method for detecting and monitoring minimal residual disease (MRD) in patients with chronic lymphocytic leukemia, multiple myeloma or B-cell acute lymphoblastic leukemia. Learn how advances in chemistry, bioinformatics, and NGS have changed the approach to MRD monitoring in patients with lymphoid malignancies.

Available by prescription use only. For more information about the FDA-cleared uses of clonoSEQ including sample types and test limitations visit clonoSEQ.com/technical-summary

Learning Objectives:

  • Compare and contrast NGS with other methodologies to measure MRD
  • Understand how clonoSEQ® can identify and track MRD to aid in clinical management decisions for patients with lymphoid malignancies
  • Review single-institution experience across disease spectrum including chronic lymphocytic leukemia multiple myeloma, and B-cell acute lymphoblastic leukemia

Join us and you will:

  • Be able to compare and contrast NGS with other methodologies to measure MRD
  • Understand how clonoSEQ® can identify and track MRD to aid in clinical management decisions for patients with lymphoid malignancies
  • Review single-institution experiences across the disease spectrum, including chronic lymphocytic leukemia, multiple myeloma, and B cell acute lymphoblastic leukemia

Available On-Demand

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Pathologist site. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register